Results 1 to 10 of about 1,445,898 (417)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia. [PDF]

Open Access Maced J Med Sci, 2019
BACKGROUND: Detection of minimal residual disease (MRD) in the early phase of therapy is the most powerful predictor of relapse risk in children with acute lymphoblastic leukaemia (ALL).
Jovanovska A, Martinova K, Kocheva S, Trajkova-Antevska Z, Coneska-Jovanova B, Panovska-Stavridis I, Stankovikj S, Trajkova S, Dimovski A.   +8 more
europepmc   +4 more sources

Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Arthritis Research & Therapy, 2018
Background The aim of this study was to assess the outcomes of remission induction in patients with IgG4-related disease (IgG4-RD) in our cohort, and to investigate the characteristics, prognosis, and risk factors in the patients failed of remission ...
Liwen Wang, Panpan Zhang, Mu Wang, Ruie Feng, Yamin Lai, Linyi Peng, Yunyun Fei, Xuan Zhang, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang, Wen Zhang   +11 more
doaj   +2 more sources

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.

JAMA, 2021
Importance The current standard induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis is the combination of high-dose glucocorticoids and cyclophosphamide or rituximab.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H, LoVAS Collaborators.   +19 more
europepmc   +2 more sources

Comparison of early versus late addition of granulocyte and monocyte adsorption for incomplete remission induction in ulcerative colitis [PDF]

JGH Open
Background and aim Ulcerative colitis (UC) is characterized by repeated relapse and remission. Because no fundamental therapeutic strategy has been established, the treatment goal is generally to maintain the remission phase for a long period after rapid
Keiichi Tominaga, Mimari Kanazawa, Shoko Watanabe, Takanao Tanaka, Shunsuke Kojimahara, Satoshi Masuyama, Keiichiro Abe, Akira Kanamori, Akira Yamamiya, Takeshi Sugaya, Kenichi Goda, Yuji Fujita, Shigemi Yoshihara, Yasuo Haruyama, Atsushi Irisawa   +14 more
doaj   +2 more sources

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Arthritis Research & Therapy, 2018
Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction ...
Josef S. Smolen, Annette Szumski, Andrew S. Koenig, Thomas V. Jones, Lisa Marshall   +4 more
doaj   +2 more sources

Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis

Arthritis Research & Therapy, 2017
Background Microscopic polyangiitis (MPA), which is classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis, is one of the most frequent primary vasculitides in Japan.
Akihiro Ishizu, Utano Tomaru, Sakiko Masuda, Ken-ei Sada, Koichi Amano, Masayoshi Harigai, Yasushi Kawaguchi, Yoshihiro Arimura, Kunihiro Yamagata, Shoichi Ozaki, Hiroaki Dobashi, Sakae Homma, Yasunori Okada, Hitoshi Sugiyama, Joichi Usui, Naotake Tsuboi, Seiichi Matsuo, Hirofumi Makino, for the Research Committee of the Intractable Vasculitis Syndrome and the Research Committee of the Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan   +18 more
doaj   +2 more sources

Glutamine for induction of remission in Crohn's disease [PDF]

Cochrane Database of Systematic Reviews, 2016
Crohn's disease is a chronic relapsing condition of the alimentary tract with a high morbidity secondary to bowel inflammation. Glutamine plays a key role in maintaining the integrity of the intestinal mucosa and has been shown to reduce inflammation and disease activity in experimental models of Crohn's disease.To evaluate the efficacy and safety of ...
Akobeng, Anthony, Elawad, M, Gordon, Morris   +2 more
openaire   +4 more sources

Probiotics for induction of remission in Crohn's disease [PDF]

Cochrane Database of Systematic Reviews, 2008
Crohn's disease has a high morbidity and there is no known cure. Current treatments have multiple side effects and an effective treatment with minimal side effects is desired. Probiotics have been proposed as such a treatment but their efficacy is undetermined.
Andrew D Butterworth, Adrian G. Thomas, Anthony K Akobeng   +2 more
openalex   +3 more sources

Remission induction in acute myeloid leukemia [PDF]

International Journal of Hematology, 2012
Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) has become the standard of ...
Eytan M. Stein, Martin S. Tallman
openalex   +5 more sources

Traditional corticosteroids for induction of remission in Crohn's disease [PDF]

Cochrane Database of Systematic Reviews, 2008
Historically, corticosteroids have been the most commonly used class of medication for induction of remission in Crohn's disease (CD). Corticosteroids down regulate production of inflammatory cytokines and interfere with NF-kappaB production, thereby blunting inflammatory response.The primary objective was to systematically review the efficacy and ...
Eric I. Benchimol, Cynthia H. Seow, A. Hillary Steinhart, Anne M. Griffiths   +3 more
openalex   +4 more sources